Open-label study of high (30 mg) and moderate (20 mg) dose escitalopram for the treatment of obsessive-compulsive disorder.

摘要: This study sought to investigate the efficacy of escitalopram at different dosages for treatment obsessive-compulsive disorder (OCD). Thirty individuals were enrolled in a 16-week, open-label trial and randomly assigned 20 or 30 mg arm. Study measures assessing OCD symptoms, anxiety, depression, quality life administered baseline weeks 2, 4, 8, 12, 16. For 23 completers, pretreatment posttreatment analyses revealed significant improvements (P<0.05) on clinician-rated self-rated life, depression. Approximately half sample (n = 12) satisfied full medication response criteria less than one-quarter 5) partial responders. Intention-to-treat showed similar all measures. At completion, superior responder rate more improvement Yale-Brown Obsessive Compulsive Scale was reported those versus The difference between two groups, however, disappeared when initial differences depression anxiety scores used as analysis covariates. These results suggest that (vs. mg) dose may provide reduction symptoms sufferers with comorbid and/or anxiety.